

# Gemini Stock Analysis Report

---

Based on the detailed technical and fundamental analysis report provided for **SUNPHARMA.NS**, here is my assessment.

## Step 1: Audit the Data

- **Data Present:**
  - **Price Structure:** Daily and Weekly candlestick charts with EMA overlays (20, 50, 200).
  - **Trend Indicators:** Supertrend, MACD, Moving Averages.
  - **Momentum/Volatility:** RSI, Bollinger Bands, Volatility Squeeze analysis.
  - **Volume:** Volume moving averages and divergence analysis.
  - **Fundamentals:** Revenue, Net Income, ROE, and EPS trends (Long-term & Short-term).
  - **Relative Strength:** Comparison against the benchmark index (^CNXPHARMA).
- **Data Missing:**
  - None. The report is comprehensive for a technical positional trade assessment.
- **Confidence Level: High.** The report provides valid multi-timeframe technical signals and fundamental context necessary to make an informed decision.

## Step 2: Analyze the Setup

- **Trend Status (Bearish):** The stock is in a confirmed intermediate-term downtrend. Crucially, the price (1668.90) has closed below the **200-day EMA (1703.78)**. This is a major technical violation for positional traders, often signaling a shift from a bull market to a correction or bear phase. The Supertrend is also in a "Sell" state across Weekly, Daily, and 15-minute timeframes.
- **Momentum:** Momentum is strongly negative. The MACD is bearish with expanding negative histograms. The stock is trading below its Lower Bollinger Band (1678.83), indicating extreme weakness, though this can sometimes precede a "snap-back" mean reversion.
- **Relative Strength:** The stock has an RS Score of 49.2/100 and is classified as "Neutral," but the RS line is lagging behind the Pharma sector. It is not showing leadership qualities at this moment.
- **Support & Resistance:**
  - **Immediate Resistance:** 1703 (200 EMA) and 1731 (20 EMA).
  - **Support:** With the breakdown of current levels, the next significant structural support on the 3-year chart appears to be in the 1550-1600 zone.
- **Conclusion:** This is currently a "falling knife." While the RSI (32.13) suggests the stock is oversold, the breakdown of the 200 EMA suggests structural weakness. Entering long now would be counter-trend trading, which contradicts a high-probability positional strategy.

## Step 3: Formulate the Recommendation

**Should you enter this stock now? NO.**

**Reasoning:** The risk-to-reward ratio is unfavorable for a long position. The stock has broken major support (200 EMA) and faces a "wall" of resistance overhead (EMAs 20, 50, and 200 are clustered between 1700 and 1736). We require proof of accumulation or a trend reversal before committing capital.

**Conditional Plan (Watchlist Strategy):** You should only consider entering if the stock repairs the technical damage by reclaiming key moving averages.

- **Condition to Buy:** The price must close decisively **above the 200-day EMA** and preferably the 20-day EMA to confirm the false breakdown. Wait for a Daily Close > 1715.
- **Entry Price: INR 1720** (Buy stop order above the resistance cluster).

# Gemini Stock Analysis Report

---

- **Stop Loss: INR 1640** (Risk of ~4.6%. Placed below the current swing low/volatility bands to prevent shakeouts).
- **Take Profit: INR 1860** (Target of ~8.1%. Testing the recent highs and upper resistance zones).

*Note: If the price continues to drop below 1640 without triggering the entry condition, cancel this plan and look for stabilization at the 1550 support level.*

## News & Analyst Targets

As a stock research analyst, I have compiled the latest developments, brokerage views, and analyst targets for **Sun Pharmaceutical Industries Ltd. (SUNPHARMA)** for the week ending **January 17, 2026**.

### 1) Latest News for SUNPHARMA (Week of Jan 11-17, 2026)

- **US Launch of Unloxcyt (Key Development):** On **January 15, 2026**, Sun Pharma announced the launch of **Unloxcyt (cosibelimab-ipdl)** in the US market. The drug is indicated for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or radiation. This is a significant milestone for its specialty portfolio.
- **Trading Window Closure:** The trading window for dealing in Sun Pharma shares has been closed effective **January 1, 2026**, and will remain closed until 48 hours after the declaration of the unaudited financial results for the quarter ended December 31, 2025 (Q3 FY26).
- **SPARC EGM Notice:** On **January 17, 2026**, the company's research arm, Sun Pharma Advanced Research Company (SPARC), published notices regarding an upcoming Extraordinary General Meeting (EGM), signaling potential corporate actions or approvals in the pipeline.
- **Regulatory Status (Baska Facility):** Investors are monitoring the **"Official Action Indicated" (OAI)** classification issued by the US FDA for the company's **Baska** manufacturing facility in India. This status, confirmed in late December/early January, implies that regulatory and administrative actions may be recommended, potentially delaying future approvals from this site.

### 2) Upgrade/Downgrade from Brokerages

- **Choice Equity Broking:** Issued a fresh recommendation on **January 7, 2026**, with a "Buy" view and a target price of **INR 1,825**.
- **Prabhudas Lilladher:** Maintained a **"Buy"** rating. In a recent update following the Unloxcyt launch, the brokerage revised its target price upward to **INR 2,275**, citing the successful launch of key specialty assets (Leqselvi and Unloxcyt) as pivotal for future growth.
- **Consensus View:** The broader analyst consensus remains positive ("Buy" to "Outperform"), though some brokerages like **Nuvama** have maintained a more cautious "Hold" stance due to valuation concerns and regulatory headwinds.

### 3) Other News Impacting SUNPHARMA

- **Sector Outlook (Jefferies):** Global brokerage Jefferies has described FY26 for the Indian pharma sector as a "tale of two halves," predicting a weaker first half followed by a recovery. Sun Pharma is seen as relatively insulated compared to peers like Dr. Reddy's due to its lower dependence on specific high-competition generics (like gRevlimid) and its strong specialty pipeline.
- **US Generic Pricing:** The sector continues to face pricing pressure in the US generic market. However, Sun Pharma's pivot toward **Specialty Medicines** (now a significant portion of global sales) is acting as a buffer against this erosion.
- **Nifty 50 Dynamics:** The stock continues to see institutional interest as a stable heavyweight in the Nifty 50, often acting as a defensive bet during broader market volatility.

### 4) Latest Analyst Targets (2026)

# Gemini Stock Analysis Report

Below is the summary of the latest available price targets from major brokerages.

Brokerage Firm	Rating	Target Price (INR )	Key Rationale / Notes
Motilal Oswal	BUY	2,280	Strong specialty pipeline execution and domestic leadership.
Prabhudas Lilladher	BUY	2,275	Revised upward post-Unlloxcyt & Leqselvi launch; growth visibility in specialty.
Morgan Stanley	Overweight	2,026	Sustained domestic growth and specialty ramp-up offset US generic weakness.
Macquarie	Outperform	2,000	Revenue/EBITDA beating estimates; strong India & EM performance.
Choice Equity	BUY	1,825	Fresh recommendation; sees upside from current levels.
Nuvama	HOLD	1,830	Cautious on valuation and regulatory risks (OAI status).
Consensus Mean	BUY	~1,965	Average of polled analysts (as of Jan 17, 2026).

**Disclaimer:** Stock investments are subject to market risks. The targets above are based on analyst reports available as of Jan 17, 2026, and may change based on upcoming Q3 FY26 results.


# Stock Detailed Analysis Report

## **SUNPHARMA.NS**

Current Price: ₹1668.90

Generated: 2026-01-17 17:59

# SUNPHARMA.NS - 3 Year Daily Price Chart



## Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	8.97%	10.64%
Net Income	Yes	No	14.12%	49.47%
ROE	Yes	No	0.61%	30.45%
EPS	Yes	No	14.29%	49.67%

## Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	7.57%	2.54%
Net Income	No	5.99%	-4.31%
ROE	No	-32.32%	-32.32%
EPS	Yes	-4.72%	1.45%

# SUNPHARMA.NS - Relative Strength Analysis

## == OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	<b>Neutral</b>
RS Score:	49.2/100
:	

## == RS RATIOS ==:

1M RS:	<b>0.978 [Neutral]</b>
3M RS:	<b>0.980 [Neutral]</b>
6M RS:	<b>0.994 [Neutral]</b>
1Y RS:	<b>0.993 [Neutral]</b>
:	

## == TURNAROUND ANALYSIS ==:


Turnaround Status:	<b>Not Detected</b>
:	

## SIGNAL CRITERIA::


✗ Emerging RS:	<b>Not accelerating</b>
✓ Medium-term Lagging:	6M=0.994, 1Y=0.993 ( $\leq 1.0$ )
✓ Performance Improving:	3M (+0.8%) > 6M (-3.4%)

Relative Strength Analysis: SUNPHARMA.NS vs ^CNXPBARMA  
Classification: Neutral


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline





## SUNPHARMA.NS - EMA Crossover Summary

EMA 20:	1731.30
EMA 50:	1736.50
EMA 200:	1703.78
Trend Status:	<b>Short-term Downtrend</b>
Golden Cross Date:	2025-11-14 00:00:00+05:30
Golden Cross Price:	1757.10


SUNPHARMA.NS EMA Crossover Analysis



## SUNPHARMA.NS - Bollinger Bands Summary

<b>Current Price:</b>	1668.90
<b>Upper Band:</b>	1783.44
<b>Middle Band (SMA 20):</b>	1731.13
<b>Lower Band:</b>	1678.83
<b>%B:</b>	-0.0949
<b>Band Width:</b>	0.0604
<b>Status:</b>	Below Lower Band
<b>Signal:</b>	None
<b>Recent Signal 1:</b>	<b>Sell Signal at 2025-12-01 00:00:00+05:30</b>


SUNPHARMA.NS Bollinger Bands (20, 2) Analysis



## SUNPHARMA.NS - Supertrend Summary

Status:	<b>DOWNTREND (Sell)</b>
Supertrend Value:	1768.31
Signal Identified On:	2025-12-18

Supertrend Analysis for SUNPHARMA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




## SUNPHARMA.NS - MACD Summary

MACD Line:	-15.19
Signal Line:	-9.14
Histogram:	-6.05
Trend:	<b>Bearish</b>
Momentum:	<b>Strengthening</b>
Signal:	None

SUNPHARMA.NS Price



SUNPHARMA.NS MACD (12, 26, 9)








## SUNPHARMA.NS - Volatility Squeeze Summary

<b>BB Width:</b>	0.0604
<b>ATR:</b>	28.2214
<b>Total Signals:</b>	26
<b>Signal 1:</b>	ATR Contraction at 2026-01-02 00:00:00+05:30 (Price: 1728.00)
<b>Signal 2:</b>	ATR Contraction at 2026-01-05 00:00:00+05:30 (Price: 1728.90)
<b>Signal 3:</b>	ATR Contraction at 2026-01-06 00:00:00+05:30 (Price: 1760.20)
<b>Signal 4:</b>	ATR Contraction at 2026-01-07 00:00:00+05:30 (Price: 1782.60)
<b>Signal 5:</b>	BB Squeeze at 2026-01-14 00:00:00+05:30 (Price: 1700.70)




# SUNPHARMA.NS - Volatility Squeeze Analysis



# SUNPHARMA.NS - RSI-Volume Summary

Current RSI:	32.13
Current Volume:	3697596
Volume MA 20:	1747530
Bullish Divergences:	1
Bearish Divergences:	3
Bullish Div 1:	Date: 2025-06-04 00:00:00+05:30, Price: 1659.44
Bearish Div 1:	Date: 2024-04-01 00:00:00+05:30, Price: 1609.07
Bearish Div 2:	Date: 2025-07-30 00:00:00+05:30, Price: 1733.80

# SUNPHARMA.NS RSI-Volume Divergence Analysis



# SUNPHARMA.NS - Volume Analysis

## == VOLUME ANALYSIS ==:

Status:

**156 Signals Detected**

:

**2025-12-19 [-]:**

Distribution Day

**2025-12-24 [-]:**

Distribution Day

**2025-12-26 [-]:**

Distribution Day



**2025-12-29 [+]:**

**Selling Exhaustion (Bullish Div)**

**2026-01-08 [-]:**

Distribution Day

# SUNPHARMA.NS - Volume Analysis



## Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	DOWNTREND (Sell)	1827.17	1668.9	2026-01-12
1 Day	DOWNTREND (Sell)	1768.31	1668.9	2025-12-18
15 Min	DOWNTREND (Sell)	1678.81	1668.9	2026-01-14

## Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bearish	Strengthening	Bearish Crossover (Sell)
1 Day	Bearish	Strengthening	No Signal
15 Min	Bullish	Strengthening	No Signal

SUNPHARMA.NS - 1 Week (Candlestick + EMAs)



SUNPHARMA.NS - 1 Day (Candlestick + EMAs)




SUNPHARMA.NS - 15 Min (Candlestick + EMAs)





## Trendlyne Snapshot - SUNPHARMA\_main



Durability score <sup>1</sup>

65.0 / 100

High Financial Strength

Valuation Score <sup>1</sup>

31.3 / 100

Mid Valuation

Momentum Score <sup>1</sup>

44.8 / 100

Technically Neutral

Mid-range Performer

These stocks have strong quality. Their reasonable financials and technicals make them potentially attractive to i...

View Similar

Embed DVM <sup>1</sup>

16

S

W

7

1

O

T

2

SWOT Analysis <sup>1</sup>

Check Before You Buy

VIEW FULL CHECKLIST

High rank 15 Positive \* 8 Negative

65.2% Pass in checklist

0 45 55 100

PE Valuation Check

VIEW FULL CHECKLIST

Right Now <sup>1</sup>

Undervalued 29.7%

1 Year Forward <sup>1</sup>

Undervalued 44.7%

INSIGHT Sun Pharmaceutical is undervalued at both current PE and future earnings esti...

Analyst Price Target <sup>1</sup>

FORECASTER

1,965

1Yr Price target upside is 18%

Sun Pharmaceutical Key Metrics

Preset Metrics Preset Metrics

ROE Ann. % <sup>1</sup> Above Industry Median	15.1	Broker Average Target <sup>1</sup> 15.13% upside	1,921.38	Market Capitalization <sup>1</sup> Market Leader	400,425	Price to Book <sup>1</sup> Above Industry Median
--------------------------------------------------	------	-----------------------------------------------------	----------	-----------------------------------------------------	---------	-----------------------------------------------------

DVM

Key Metrics

Price Chart

Forecaster

Financials

Technicals

Shareholding


Deals

Documents

Corporate actions

Company Profile <sup>1</sup>

Trendlyne Snapshot - SUNPHARMA\_forecaster



Sun Pharmaceutical - SUNPHARMA - stock price prediction, stock forecast, target price, analyst ratings from 38 analysts

Sun Pharmaceutical has a share price target of Rs 1965, revenue growth forecast of 9.2%, and profit growth estimate of 2.6% for FY26, based on top 38 analyst calls.

Sun Pharmaceutical **FORECASTER** - Analyst Estimates <sup>1</sup>

[FORECASTER DASHBOARD](#) →

